Lactobacillus plantarum N13 and Reduced Liver Fibrosis

• The postbiotic ReFerm® versus standard nutritional support in advanced alcohol-related liver disease (GALA-POSTBIO): a randomized controlled phase 2 trial.

  • 2025-07-01
  • RCT · n = 56
  • Nature communications 16(1)
  • • Johanne K Hansen
    • Mads Israelsen
    • Suguru Nishijima
    • Sara E Stinson
    • Peter Andersen
    • Stine Johansen
    • Camilla D Hansen
    • Maximilian Joseph Brol
    • Sabine Klein
    • Robert Schierwagen
    • Frank Erhard Uschner
    • Karolina Sulek
    • Ida F Villesen
    • Katrine P Lindvig
    • Katrine H Thorhauge
    • Nikolaj Torp
    • Jane M Jensen
    • Marisa Isabell Keller
    • Gitte H Jensen
    • Sönke Detlefsen
    • Diana J Leeming
    • Evelina Stankevic
    • Tommi Suvitaival
    • Andressa Zawadzki
    • Michael Kuhn
    • Lars Juhl Jensen
    • Morten Karsdal
    • Jonel Trebicka
    • Hans Israelsen
    • Cristina Legido-Quigley
    • Peer Bork
    • Manimozhiyan Arumugam
    • Torben Hansen
    • Maja Thiele
    • Aleksander Krag

  • PubMed: 40595534
  • DOI: 10.1038/s41467-025-60755-9

  2 Insights on

  • Reduced Liver Fibrosis

  • High evidence
  • Rigorous Journal

  This reduction was observed in 29% of patients receiving ReFerm®, compared to 14% with Fresubin® (OR = 2.40; 95% CI 0.63 to 9.16; p = 0.200).

  Effect

  Beneficial

  Effect size

  Small

  Significant

  No